|
Accueil > Actualité
AstraZeneca: Tezspire effective against rhino-sinusitis
(CercleFinance.com) - AstraZeneca and Amgen announced this weekend that the phase III 'WAYPOINT' trial demonstrated the efficacy of Tezspire (tezepelumab) in reducing the severity of nasal polyps, the need for surgery and systemic corticosteroid therapy in patients with chronic rhino-sinusitis with nasal polyps.
Tezspire significantly improved nasal polyp score (NPS) and nasal congestion from the first weeks of treatment, with benefits maintained over 52 weeks. The study showed a 98% reduction in the need for surgery and an 88% reduction in the use of corticosteroids. The results were published in the New England Journal of Medicine and presented at the AAAAI/WAO congress. Copyright (c) 2025 CercleFinance.com. All rights reserved. |
22/05/2025 07:20
Sanofiaccord pour l'acquisition de Vigil Neuroscience 21/05/2025 18:42 Erametréalise un placement d'obligations de 100 ME 21/05/2025 18:34 OSE Immunocollaboration autour des thérapies à base d'ARNm 21/05/2025 18:28 Crédit Agricolesigne un nouveau partenariat avec Crelan 21/05/2025 18:21 Maurel & Promconstruction d'une centrale solaire en Angola 21/05/2025 18:17 Spiea réalisé une émission obligataire de 600 ME Tous les articles sociétés |
